GF Fund Management’s Design Therapeutics DSGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$16.5K Buy
1,315
+106
+9% +$1.46K ﹤0.01% 509
2026
Q2
$17.5K Sell
1,209
-62
-5% -$773 ﹤0.01% 494
2026
Q1
$13.5K Buy
1,271
+153
+14% +$1.55K ﹤0.01% 535
2025
Q4
$10.5K Sell
1,118
-95
-8% -$744 ﹤0.01% 570
2025
Q3
$9.13K Sell
1,213
-236
-16% -$1.18K ﹤0.01% 560
2025
Q2
$4.88K Hold
1,449
– – ﹤0.01% 628
2025
Q1
$5.59K Buy
1,449
+260
+22% +$1.24K ﹤0.01% 617
2024
Q4
$7.34K Buy
+1,189
New +$6.88K ﹤0.01% 581

Other funds holding DSGN

GF Fund Management's DSGN Position: Q3 2026 in Review

GF Fund Management increased its Design Therapeutics (DSGN) stake by 8.8% in Q3 2026, buying an estimated $1.46K and bringing the position to 1,315 shares worth $16.5K. The position accounts for ﹤0.01% of the portfolio, ranked #509.

GF Fund Management first reported a position in DSGN in Q4 2024 and has held it in 8 quarters since. The position peaked at $17.5K in Q2 2026. 142 funds tracked by Wall St. Rank hold DSGN as of Q3 2026.

  • GF Fund Management held 1,315 shares of Design Therapeutics worth $16.5K as of Q3 2026.
  • GF Fund Management bought 106 Design Therapeutics shares in Q3 2026, an estimated $1.46K.
  • Design Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #509 holding.
  • GF Fund Management first reported a position in Design Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • GF Fund Management's Design Therapeutics position peaked at $17.5K in Q2 2026.
  • 142 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.